Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Pareto Securities Healthcare Conference Stockholm 2019
24 slides from Cantargia Ab's conference presentation, September 2019
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: Cantargia
Cantargia Current owners (June 30, 2019) • Specialized in antibody therapy/immunology/oncology Sunstone 8.2% • Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020 Alecta 6.6% • Platform around IL1RAP, lead candidate for autoimmunity and
Slide 4: Cantargia – opportunity to save lifes and create value
Cantargia – opportunity to save lifes and create value • Potentially more effective treatment against novel target in clinically validated pathway • Right team and clear plan to position our projects and maximize value • First in class platform technology against novel target 4
Slide 5: Cantargia core – tumor inflammation
Cantargia core – tumor inflammation Intrinsic pathway Immune suppression Genome instability Tumor-promoting Metastases and mutation inflammation Resistance to therapy Extrinsic pathway Cancer caused by two enablers: • Genomic instability/mutations • Inflammation Counteracting inflammation - strategy
Slide 6: Validating study – counteracting tumor inflammation
Validating study – counteracting tumor inflammation Canakinumab phase 3 trials (compl CANTOS trial (n=10061) 20121/2022) • Canakinumab (Novartis) • Reduced lung cancer incidence by 67 Adjuvant NSCLC (CANOPY-A) 1500 patients After surgery, no mets, placebo control % and death by 77 %. First line (CAN
Slide 7: CAN04 (nidanilimab) added value vs canakinumab
CAN04 (nidanilimab) added value vs canakinumab Canakinumab • Antibody directed against one of the two IL-1 ligands, IL-1β CAN04: Double mechanism • Binds the signaling receptor and counteracts both ligands • Induce killing via the immune system (ADCC) ..Cantargia has patents on IL1RAP 7 CAN04 has a
Slide 8: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Phase I/IIa trial - NSCLC and pancreatic cancer • Phase I data presented orally at ASCO 2019 • 22 patients (NSCLC, pancreatic cancer, colon cancer) • Good safety up to 10 mg/kg • Significant effect on relevant biomarkers (IL-6, CRP) • 9 pts had stable disease up to 6 m
Slide 9: Phase I results (biomarkers and efficacy)
Phase I results (biomarkers and efficacy) • Twenty-one (21) patients had available pre- and post-treatment assessment by imaging • One patient with NSCLC had PFS for 7 months (4 prior lines of therapy, including nivolumab for 8 months) • One patient with PDAC had PFS for 5 months (Prior line of ther
Slide 10: Extensive Biomarker program
Extensive Biomarker program Phase II Phase I Purposes: • Generate clinical proof of concept • Identification of patients most likely to respond. 10
Slide 11: NSCLC strategy (metastatic disease)
NSCLC strategy (metastatic disease) -combination with first line chemotherapy 2nd line (after Keytruda) with Cisplatin/gemcitabine 1) Expansion of most Nonsquamous Squamous Mutated promising subgroup PDL1 high Keytruda Keytruda + Targeted (Biomarker defined) Cantargia Platinum Doublet therapies 2) P
Slide 12: Pancreatic cancer strategy
Pancreatic cancer strategy First line patients included in CANFOUR combination arm Treatment Goal Resectable Surgery Cure Locally advanced Chemotherapy Response, surgery Metastatic Chemotherapy Response 1) Expansion of best subgroup (locally advanced/metastatic/biomarker) 2) Preparation for pivotal
Slide 13: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need • Cantargia founded based on: • Discovery of IL1RAP on cancer cells • Antibodies against IL1RAP - antitumor effects • IP on antibody therapy against IL1RAP • Primary indications. NSCLC and pancreatic cancer • Biomarker studies ongoing, identify patient
Slide 14: Two major preclinical findings during 2018 - new opportunities
Two major preclinical findings during 2018 -new opportunities Synergisitic effects with Binding to immune cells chemotherapy in tumor microenvironment -Stronger antitumor effects -Antimetastatic effects -Counteracts chemotherapy toxicity -Counteract immune suppression 14
Slide 15: CAN04 counteract metastases
CAN04 counteract metastases • Cancer cells (seeds) needs a good soil to form a metastasis • The IL-1 system (inflammation) can provide such environment (soil) • Data generated in 4T1 (TNBC) model (n=10) A tumor can create its own ”seed and soil” 15 CAN04 blocks the ability for metastic cells to stic
Slide 16: CAN04 attacks several cell types in the tumor
CAN04 attacks several cell types in the tumor CAN04 is relevant to several parts of cancer progression 16
Slide 17: Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine
Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine • CAN04 increases antitumor effects of platinum compounds (cisplatin, carboplatin, oxaliplatin) • CAN04 counteracts toxicity from platinum compounds • Cisplatin/Gemcitabine standard chemotherapy for several cancer forms 10 mice p
Slide 18: CANTOS additional findings (from Novartis IL-1β antibody)
CANTOS additional findings (from Novartis IL-1β antibody) -identification of additional opportunities CANCER decreased risk of death with treatment (high dose) Lung cancer 77 % P=0.0002 Non-lung cancer 37 % P=0.06 Decreased incidence of inflammatory disease (all doses) Arthritis 32% p<0.0001 Ostheoa
Slide 19: IL1RAP platform to treat serious diseases
IL1RAP platform to treat serious diseases • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, CA) Selection of clinical candidate
Slide 20: Significant value inflection points ahead of CANFOUR results
Significant value inflection points ahead of CANFOUR results 2019 • US regulatory and clinical strategy • Phase IIa monotherapy results • Clinical progress and initial phase IIa results • Preclinical progress (immuno-oncology effects, combinations etc) • CANxx progress • US clinical trial 2020 • Pha
Slide 21: Management
Management Göran Forsberg Liselotte Larsson CEO since 2014, born 1963 VP Operations since 2014, born 1963 Ph.D Biochemistry, Assoc Prof. PhD in biotechnology 30+ years experience in Biotech/Pharma (KabiGen, Pharmacia, Active 20+ years in pharmaceutical/biotechnology companies (BioGaia Biotech and th
Slide 22: Board of Directors
Board of Directors Magnus Persson Karin Leandersson Chairman of the Board since 2016, born 1960 Board member since 2016, born 1972 MD and assoc prof in physiology at Karolinska Institutet in Stockholm. Professor in tumour immunology at Lund University. Extensive experience in medicine, life sciences
Slide 23: Lead project CAN04 in the highest growth segment – Oncology antibodies
Lead project CAN04 in the highest growth segment– Oncology antibodies Sales cancer therapeutic antibodies 2018 (2017) Rituxan/MabThera CHF 5.19bn (5.83bn) Avastin CHF 6.85bn (6.69bn) Herceptin CHF 6.98bn (7.01bn) Immuno-oncology driving market growth 2018 (2017) Opdivo $6.74bn ($4.95bn) Keytruda $7.
Slide 24: Cantargia
Cantargia Current owners (June 30, 2019) • Specialized in antibody therapy/immunology/oncology Sunstone 8.2% • Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020 Alecta 6.6% • Platform around IL1RAP, lead candidate for autoimmunity and
Cantargia — Pareto Securities Healthcare Conference Stockholm 2019 on 6ix